Donna-Bea Tillman AU/OPM II December 2004

Slides:



Advertisements
Similar presentations
Project L.O.F.T. Report May 2007 through October 2007 Creating a design to meet stakeholder desires and dissolve our current set of interacting problems.
Advertisements

Dr Linda Allin Division of Sport Sciences The value of real life evaluation research for student learning and employability in Sports Development.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
The Challenge and Importance of Evaluating Residents and Fellows Debra Weinstein, M.D. PHS GME Coordinators Retreat March 25, 2011.
BME-IDEA Workshop, September 28, 2005
Strengthening Health Research Capacity of Nurses – The Need for Evidence Based Practice Dr. Shareen Swastika Ali ( BDS,PGDETT,MPH) Health Research Officer.
The Fellowships aim to: Educate scientists and engineers on the intricacies of federal policymaking Provide scientific and technical knowledge to support.
Aligning Employee Performance with Agency Mission
Lessons Learned in Initiating and Conducting Risk Assessments within a Risk Analysis Framework: A FDA/CFSAN Approach Robert Buchanan DHHS Food and Drug.
Introduction to Regulation
Becker Grand Rounds: Wally Pellerite June 30, 2011.
The FDA’s Role in Medicine Safety and Use
Premarket Review Performance Goals Donna-Bea Tillman Director, Office of Device Evaluation Director, Office of Device Evaluation Don St. Pierre Deputy.
Click the mouse button or press the space bar to display information. How many people know a lot about their family health history? Why is this important?
1. PBIS Team: Establishing a Foundation for Collaboration and Operation Establishing a Foundation for Collaboration and Operation – PBIS requires some.
Center for Devices and Radiological Health U. S. Department of Health and Human Services Al Taylor Acting Chief, Medical Electronics Branch Office of Science.
Career Opportunities in Statistics John Borkowski Montana State University Panel Discussion Pattaya Conference on Statistics Pattaya, Thailand.
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
Prepare for Change Ideas for Today and Tomorrow. Change is inevitable: Internal Factors Aging infrastructures Aging workforce Projects vs. programs New.
UTIA Promotion & Tenure Workshop May 19, 2015 UTIA Promotion & Tenure Workshop May 19, 2015 Overall Philosophy: Maximize faculty FTE while maintaining.
Outcomes of Public Health
Practical Placements & the QAA and ASET Guidelines By Ian Sunley & Lorna Uden Faculty of Computing, Engineering & Technology, Staffordshire University,
Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.
Module 2.1 Finance and Administration Cabinet Organizational Changes and Agency Impact March
CHILDREN, YOUTH AND WOMEN’S HEALTH SERVICE New Executive Leadership Team 15 December 2004 Ms Heather Gray Chief Executive.
FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.
Steps for Success in EHR Planning Bill French, VP eHealth Strategies Wisconsin Office of Rural Health HIT Implementation Workshop Stevens Point, WI August.
Elizabeth A. Martinez, MD, MHS Johns Hopkins Medical Institutions September 10, 2008 Organization of Care and Outcomes in Cardiac Surgery AHRQ grant 1K08HS A1.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
Crosswalk of Public Health Accreditation and the Public Health Code of Ethics Highlighted items relate to the Water Supply case studied discussed in the.
Research Peer-Review at CDER Past and Present Jerry M. Collins, Ph.D. Director, Laboratory of Clinical Pharmacology, OTR Acting Director, Division of Applied.
Outcomes Tier 2 – PI-LDP Course Tier 3 – ATP or mini-ATP Tier 1 – ACT Program Three Tiers of QI TrainingAbstract DEVELOPMENT OF FACULTY MENTORS IN QUALITY.
Celeste F. Bové, M.A., CCC-A Senior Science Policy Analyst Office of Science Coordination & Communication Food and Drug Administration FDA Participation.
1 U.S. Food and Drug Administration International Programs Melinda K. Plaisier Assistant Commissioner for International Programs U.S. Food and Drug Administration.
What GPOs are Doing to Promote Ethical Compliance Megan Barry VP, Ethics and Compliance Premier, Inc.
PBIS Team: Establishing a Foundation for Collaboration and Operation.
2 Patient Family Advisory Councils- Creating Lasting Impact Kris White, MBA, BSN, RN.
AAHRPP ACCREDITATION (Association for the Accreditation of Human Protection Programs)
Component 1: Introduction to Health Care and Public Health in the U.S. 1.1: Unit 2: Health Care Settings 1.2 a: Overview and the Organization of Federal.
Archived File The file below has been archived for historical reference purposes only. The content and links are no longer maintained and may be outdated.
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
Comments on the Liberal government’s Chief Science Officer Ted Hsu Liberal Science and Technology Critic in the 41 st Parliament.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.
From Data to Decisions: Building an Analytics Culture July 11, 2013 Project Management Institute Washington, DC Chapter.
Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
Enabling Collaborative Leadership Pioneer Programme A very brief introduction.
Integrating the Life Sciences from Molecule to Organism The American Physiological Society Conscious Choice and Serendipity in Your Career Trajectory:
Documentation Requirements for Hospital Accreditation -By Global Manager Group.
Communication and Optimal Resolution (CANDOR) Toolkit Module 4: Event Reporting, Event Investigation and Analysis.
Transforming Government, Transforming Communities Strengthening the Federal Workforce to Help Communities Implement Place-Based Initiatives Transforming.
WORKFORCE DEVELOPMENT DOMAIN TASK FORCE Rebecca Jackson, MD Co-Lead.
1 Copyright © 2012 by Mosby, an imprint of Elsevier Inc. Copyright © 2008 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 40 The Nurse Leader in.
Developing Global Family Medicine Faculty “de Novo” John G Halvorsen, MD, MS Professor Emeritus of Family and Community Medicine University of Illinois.
APPENDIX. ECBP-2- Elementary, middle, and senior high schools that provide comprehensive school health education to prevent health problems in the following.
Are You Ready to Broaden Your Horizon? Consider a Career in Preventive Medicine Physicians with Populations as their Patients.
Using core competencies in curriculum design
Promotion & Tenure Workshop
FDA Perspective on Cardiovascular Device Development
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
CDRH 2010 Strategic Priorities
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
American Society for Quality Region 5 Quality Conference
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Grant Writing Information Session
SAMPLE ONLY Dominion Health Center: Your Community Partner for Excellent Care (or another defining message) Dominion Health Center is a community health.
SAMPLE ONLY Dominion Health Center: Your Community Healthcare Home (or another defining message) Dominion Health Center is a community health center.
Presentation transcript:

Donna-Bea Tillman AU/OPM II December 2004 Use of Outside Experts in FDA’s Premarket Evaluation of Medical Devices An Action Learning Project Donna-Bea Tillman AU/OPM II December 2004 “Man’s rational life consists in those moments in which reflection not only occurs but proves efficacious.” George Santayana

FDA Mission: Historical Basis Protect the public from unsafe products I’d like to start my talk by looking back at the historical roots of FDA, which trace back to a public health protection problem. 107 people, mostly children, died when sulfanilamide, the first “wonder drug” was formulated into an elixr containing the toxin ethylene oxide. Exisiting laws did not require the drugs manufacturer to test the formulation for safety before it was sold. Congress corrected this weakness in the law the next year when it passed the Federal Food, Drug, and Cosmetic Act. This law, for the first time, required companies to prove the safety of new drugs before putting them on the market.

FDA Mission Today Promote Protect Today, FDA’s mission has broadened beyond public health protection to also include public health promotion – ensuring the availability of new products that promote the health of the American people. When most people think of FDA, they think of our public health protection role: -Historical roots of FDA -Methods well understood -Good business – basis of public confidence in medical products However, many of FDA’s most difficult challenges lay in the public health promotion arena.

FDA Organizational Chart Department of Health and Human Services Center for Veterinary Medicine Center for Food Safety And Applied Nutrition Food and Drug Administration Office of the Commissioner National Center for Toxicological Research Center for Biologics Evaluation and Research (CBER) Center for Drug Evaluation And Research (CDER) Center for Devices and Radiological Health (CDRH)

Devices are Different from Drugs Drugs Yesterday Drugs Today Drugs Tomorrow

Devices HHS/FDA/CDRH

Challenges Facing CDRH Rapid technological changes Increasing complexity of devices Public demand for more control over healthcare Global marketplace and global regulation Shrinking staff numbers … and we are being asked to make decisions more quickly than ever.

Medical Device User Fees to the Rescue!

CDRH’s New Challenge: Turning dollars into shorter review times…

…while maintaining our commitment to good science.

How are we going to make this happen?

Center for Devices and Radiological Health Office of In Vitro Diagnostic Device Evaluation and Safety Office of Device Evaluation Office of Science & Engineering Laboratories Office of Surveillance & Biometrics Center for Devices and Radiological Health Office of Management Operations Office of Communication, Education, and Rad Health Office of Compliance

CDRH Medical Device Fellowship Program CDRH established the Medical Device Fellowship Program to increase the range and depth of collaborations between CDRH and the outside scientific community. The MDFP offers short and long-term fellowship opportunities for individuals interested in learning about the regulatory process and sharing their knowledge and experience with medical devices.

Initial MDFP Goals Bring in experts in a range of disciplines. Develop a cadre of outside experts. Incorporate outside expertise into decision-making.

Where do outside experts come from? Academia Device advisory panels Practicing clinicians, engineers, others Other parts of FDA Other government agencies

Nature of appointments Short term (3 months) to longer term (2 years) Part-time or full-time Federal employment or government contract On-site or off-site

Office of Device Evaluation Office Director Division of Anesthesiology General Hospital, Infection Control, and Dental Devices Division of Reproductive, Abdominal, & Radiological Devices Office of Device Evaluation Division of General, Restorative & Neurological Devices Division of Cardiovascular Devices Division of Ophthalmic & ENT Devices

The (Initial) Problem How can CDRH most effectively use outside scientific resources to improve the premarket evaluation of medical devices?

The Group Examine pilot program in the Division of Cardiovascular Devices (DCD) Team members: BZ – Director of DCD MM – Branch chief in DCD MB – Reviewer in DCD SH – Director of MDFP LD – ODE Program Management Specialist

The Coach Explained the principles of action learning at Meeting #1, including the role of the coach Other team members were uncomfortable with assuming the role of Coach Lack of familiarity with principles of AL “Too touchy/feely” Donna-Bea agreed to be the permanent Coach

The Questioning and Reflection Process Team meeting #2: SH presents her understanding of mission and goals of MDFP program Team members engage in the “questioning process”

Meeting #2: The Questioning Process

The Questioning and Reflection Process Team asked to reflect at the end of the meeting on how things had gone Agreed that: Would work harder to keep it friendly Would build on each others questions Would refrain from asking “questions” that were opinions in disguise

Subsequent Meetings: The Questioning Process

The Questioning and Reflection Process, cont’d Medical Device review process involves lots of questions But the purpose of these questions is to get an answer “Science has promised us truth … It has never promised either peace or happiness.” Gustave Le Bon

The Questioning and Reflection Process, cont’d Action Learning has a different perspective on questions: “… seeking to go deeper, to understand, to respond to what is being asked, to give it thought. Asking questions is not only a quest for solutions but also an opportunity to explore” (Marquardt, p.31)

Core Issues How do we identify resource needs that can be appropriately filled using outside resources? How do we find the appropriate people to fill the need? What should be our selection criteria? How do we address real or apparent conflicts of interest? How do we determine the appropriate hiring mechanism and salary to use in each case?

Core Issues What do we need to do to train outside resource? What are the infrastructure needs (e.g., computers, space) required to support the program? How do we evaluate the impact of the program on our decision-making process? How do we foster staff acceptance of outside experts? How do we ensure confidentiality of proprietary information obtained by outside experts?

The Commitment to Learning Team spent time at the end of each meeting talking about how we had done as a team Particularly helpful after first few meetings Refined questioning process People’s behavior changed as a result! Demonstrated Kurt Lewin theory that the group is a powerful shaper of individual behavior

The Commitment to Learning

The Commitment to Taking Action Taking action is linked to the questioning and reflection process Need to reframe the question and get at root causes in order to determine appropriate action to take

Finding the right people Core Issues: How do we identify resource needs that can be appropriately filled using outside resources? How do we find the appropriate people to fill the need? Why are other divisions not interested in MDFP? Questioning process lead to root cause and development of actions to move forward

Medical Device Fellowship Program at end of FY04 Physicians* - 15 Visiting Scholar – senior level clinicians, surgeons Fellow - physician during fellowship training Resident – physician during residency training Engineers* - 42 Visiting Scholar – senior level engineer Co-op students Interns Physicists* - 2 Scientists* - 5 *includes students

The Commitment to Taking Action A number of issues were raised that team did NOT take action on Core Issue: How will we determine if the program is a success? Summative evaluation Objective of the program will determine the evaluation questions “It is the mark of a good action that it appears inevitable in retrospect.” Robert Louis Stevenson

Outcomes: MDFP Current Status of MDFP Next Steps Determine objectives Conduct evaluation

What I learned My role in the organization changed significantly over the course of this project Deputy Director, DCD Deputy Director, ODE Acting Director, ODE Director, ODE

What I learned What you see depends on where you stand Leader needs to be able to see things from all perspectives “Every man takes the limits of his own field of vision for the limits of the world.” Schopenhauer

What I learned The skills that I needed to be successful in the early part of my career were very different from the skills I would need to be successful in the later stages of my career “We run carelessly to the precipice, after we have put something before us to prevent us from seeing it.” Pascal

What I learned A B

Man who say it cannot be done should not interrupt man doing it. Questions? Man who say it cannot be done should not interrupt man doing it. Chinese proverb